Literature DB >> 34755438

Who's slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first-line HIV treatment in Uganda and South Africa.

Zahra Reynolds1, Suzanne M McCluskey1,2, Mahomed Yunus S Moosa3, Rebecca F Gilbert1, Selvan Pillay3, Isaac Aturinda4, Kevin L Ard1,2, Winnie Muyindike4, Nicholas Musinguzi4, Godfrey Masette4, Pravi Moodley3,5, Jaysingh Brijkumar3, Tamlyn Rautenberg6, Gavin George3, Brent A Johnson7, Rajesh T Gandhi1,2, Henry Sunpath3, Vincent C Marconi8,9,10, Mwebesa Bosco Bwana4, Mark J Siedner1,2,3,4,11.   

Abstract

OBJECTIVES: HIV virological failure remains a major threat to programme success in sub-Saharan Africa. While HIV drug resistance (HIVDR) and inadequate adherence are the main drivers of virological failure, the individual, clinical and health system characteristics that lead to poor outcomes are not well understood. The objective of this paper is to identify those characteristics among people failing first-line antiretroviral therapy (ART).
METHODS: We enrolled a cohort of adults in HIV care experiencing virological failure on first-line ART at five sites and used standard statistical methods to characterize them with a focus on three domains: individual/demographic, clinical, and health system, and compared each by country of enrolment.
RESULTS: Of 840 participants, 51% were women, the median duration on ART was 3.2 years [interquartile range (IQR) 1.1, 6.4 years] and the median CD4 cell count prior to failure was 281 cells/µL (IQR 121, 457 cells/µL). More than half of participants [53%; 95% confidence interval (CI) 49-56%] stated that they had > 90% adherence and 75% (95% CI 72-77%) took their ART on time all or most of the time. Conversely, the vast majority (90%; 95% CI 86-92%) with a completed genotypic drug resistance test had any HIV drug resistance. This population had high health system use, reporting a median of 3 (IQR 2.6) health care visits and a median of 1 (IQR 1.1) hospitalization in the preceding 6 months.
CONCLUSIONS: Patients failing first-line ART in sub-Saharan Africa generally report high rates of adherence to ART, have extremely high rates of HIV drug resistance and utilize significant health care resources. Health systems interventions to promptly detect and manage treatment failure will be a prerequisite to establishing control of the HIV epidemic.
© 2021 British HIV Association.

Entities:  

Keywords:  Africa; HIV drug resistance; first-line; treatment failure; virological failure

Mesh:

Substances:

Year:  2021        PMID: 34755438      PMCID: PMC9010349          DOI: 10.1111/hiv.13203

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.094


  43 in total

1.  The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.

Authors:  A Cozzi-Lepri; A N Phillips; B Clotet; J Kjaer; V Von Wyl; G Kronborg; A Castagna; J R Bogner; J D Lundgren
Journal:  HIV Med       Date:  2011-08-17       Impact factor: 3.180

2.  Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen.

Authors:  C Piketty; L Weiss; F Thomas; A S Mohamed; L Belec; M D Kazatchkine
Journal:  J Infect Dis       Date:  2001-03-29       Impact factor: 5.226

3.  Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa.

Authors:  Nicholas Musinguzi; Collins D Muganzi; Yap Boum; Allan Ronald; Mark A Marzinke; Craig W Hendrix; Connie Celum; Jared M Baeten; David R Bangsberg; Jessica E Haberer
Journal:  AIDS       Date:  2016-04-24       Impact factor: 4.177

4.  Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.

Authors:  Andreas D Haas; Olivia Keiser; Eric Balestre; Steve Brown; Emmanuel Bissagnene; Cleophas Chimbetete; François Dabis; Mary-Ann Davies; Christopher J Hoffmann; Patrick Oyaro; Rosalind Parkes-Ratanshi; Steven J Reynolds; Izukanji Sikazwe; Kara Wools-Kaloustian; D Marcel Zannou; Gilles Wandeler; Matthias Egger
Journal:  Lancet HIV       Date:  2015-06-16       Impact factor: 12.767

Review 5.  The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.

Authors:  Mark J Siedner; Mwebesa B Bwana; Mahomed-Yunus S Moosa; Michelle Paul; Selvan Pillay; Suzanne McCluskey; Isaac Aturinda; Kevin Ard; Winnie Muyindike; Pravikrishnen Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Brent Johnson; Rajesh T Gandhi; Henry Sunpath; Vincent C Marconi
Journal:  HIV Clin Trials       Date:  2017-07-18

6.  When patients fail UNAIDS' last 90 - the "failure cascade" beyond 90-90-90 in rural Lesotho, Southern Africa: a prospective cohort study.

Authors:  Niklaus Daniel Labhardt; Isaac Ringera; Thabo Ishmael Lejone; Molisana Cheleboi; Sarah Wagner; Josephine Muhairwe; Thomas Klimkait
Journal:  J Int AIDS Soc       Date:  2017-07-19       Impact factor: 5.396

7.  HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study.

Authors:  Francis Kiweewa; Allahna Esber; Ezra Musingye; Domonique Reed; Trevor A Crowell; Fatim Cham; Michael Semwogerere; Rosemary Namagembe; Alice Nambuya; Cate Kafeero; Allan Tindikahwa; Leigh Anne Eller; Monica Millard; Huub C Gelderblom; Babajide Keshinro; Yakubu Adamu; Jonah Maswai; John Owuoth; Valentine Chepkorir Sing'oei; Lucas Maganga; Emmanuel Bahemana; Samoel Khamadi; Merlin L Robb; Julie A Ake; Christina S Polyak; Hannah Kibuuka
Journal:  PLoS One       Date:  2019-02-05       Impact factor: 3.240

8.  Differentiated HIV care in South Africa: the effect of fast-track treatment initiation counselling on ART initiation and viral suppression as partial results of an impact evaluation on the impact of a package of services to improve HIV treatment adherence.

Authors:  Sophie Js Pascoe; Matthew P Fox; Amy N Huber; Joshua Murphy; Mokgadi Phokojoe; Marelize Gorgens; Sydney Rosen; David Wilson; Yogan Pillay; Nicole Fraser-Hurt
Journal:  J Int AIDS Soc       Date:  2019-11       Impact factor: 5.396

9.  Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study.

Authors:  Viktor von Wyl; Thomas Klimkait; Sabine Yerly; Dunja Nicca; Hansjakob Furrer; Matthias Cavassini; Alexandra Calmy; Enos Bernasconi; Jürg Böni; Vincent Aubert; Huldrych F Günthard; Heiner C Bucher; Tracy R Glass
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

10.  Reimagining HIV service delivery: the role of differentiated care from prevention to suppression.

Authors:  Anna Grimsrud; Helen Bygrave; Meg Doherty; Peter Ehrenkranz; Tom Ellman; Robert Ferris; Nathan Ford; Bactrin Killingo; Lynette Mabote; Tara Mansell; Annette Reinisch; Isaac Zulu; Linda-Gail Bekker
Journal:  J Int AIDS Soc       Date:  2016-12-01       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.